Raymond James Financial Inc Supernus Pharmaceuticals, Inc. Transaction History
Raymond James Financial Inc
- $264 Billion
- Q4 2024
A detailed history of Raymond James Financial Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 189,364 shares of SUPN stock, worth $7.36 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
189,364Holding current value
$7.36 Million% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SUPN
# of Institutions
289Shares Held
60.8MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$404 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$238 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$198 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$112 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$102 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.08B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...